GSK ordered to pay Vectura $89.7m in patent damages

British drugmaker Vectura has succeeded in its patent litigation against fellow UK pharmaceutical company GlaxoSmithKline (GSK) over a series of drugs delivered through GSK’s ‘Ellipta’ dry powder inhaler.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Vectura wins additional $10m patent damages against GSK

16 September 2019 A district court has upped Vectura’s award of $89.7 million in damages by $10m, after a jury trial earlier this year found that GlaxoSmithKline has willfully infringed one of its patents.

Big Pharma

GSK awarded Arrow declaration in patent dispute with Vectura

17 December 2018 The English High Court has ruled in favour of GSK in its patent dispute with Vectura, a UK-based pharmaceutical company which specialises in inhalable medicaments.

Americas

Vectura sues GSK for patent infringement

29 July 2016 Pharmaceutical company Vectura has sued GSK for allegedly infringing its patent after claiming that it refused to expand on a licensing agreement.

More features

How 'Boehringer' sets preliminary relief threshold for generics

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

GSK ordered to pay Vectura $89.7m in patent damages

More on this story

Editor's picks

Editor's picks

More features